## **CERTIFICATE OF EXPRESS MAIL (37 CFR 1.10)**

**Label No. EE068530369US** 

I hereby certify that the attached papers and/or fee are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service on the date shown below in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington DC 20231.

December 10, 1998

(Date)

Marie Greloch (Printed Name)

Parie Grelon

Zeneca Inc.

Docket No. PHM.70293/U.S.

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of: Aiyar, J., et al.

Serial Number:

Group Art Unit:

Filed: December 10, 1998

For: HUMAN BRAIN-DERIVED TISSUE-SPECIFIC POTASSIUM CHANNEL

**Assistant Commissioner for Patents** 

Washington, DC 20231

## INFORMATION DISCLOSURE STATEMENT **PURSUANT TO 37 C.F.R. §§ 1.97 AND 1.98**

Applicants submit herewith a list of patents and publications which Applicants believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

Applicants submit herewith also an Associate Power of Attorney giving Patrick H. Higgins, Registration No. 39,709, power of attorney for this application.

While the patents and publications disclosed herein may be "material" within the meaning of 37 C.F.R. § 1.56, Applicants' inclusion thereof in this Information Disclosure Statement is not intended to constitute an admission that any such patent or publication is "prior art" for this invention unless specifically designated as such.

PHM.70293/US Page No.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made o that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

Applicants believe that the claims of the present application distinguish patentably over the patents and publications listed herein.

This Information Disclosure Statement is being filed within three months of the filing date of the application and therefore, pursuant to 37 C.F.R. § 1.98(b), no fee or certification is required. However, in the event that it is determined that a fee is required for consideration of this Information Disclosure Statement, the Commissioner is hereby authorized to charge the requisite fee to deposit account 26-0166.

Further, it is noted that the instant application claims priority from the following United Kingdom (UK) application:

**UK** Application

9726339.6

Filing Date

December 13, 1997

Respectfully submitted,

ZENECA Inc.

Dated December 10, 1998

Zeneca Inc.

Docket No. 70293

Enclosures: Form PTO-1449

References

Patrick H. Higgins, Esq.

Attorney for Applicants Reg. No. 39,709

Telephone: 302/886-4889